Living Medical
Textbook
From Projects In Knowledge
 
Osteoporosis
Fracture Prevention and Therapeutic Management Edition
  /1892/iPhoneAd/1892iPhoneAd.gif [NO]
Chapter 1
Overview of Osteoporosis

Last Reviewed: May 20, 2010
Chapter 2
Identifying Patients at Risk for Osteoporosis and Fractures

Last Reviewed: May 20, 2010
Chapter 3
Assessment of Fracture Risk Using FRAX®

Last Reviewed: May 20, 2010
Chapter 4
Treatment of Osteoporosis

Last Reviewed: May 20, 2010
Chapter 5
Management of the Postfracture Patient

Last Reviewed: May 20, 2010
Chapter 6
Monitoring

Last Reviewed: May 20, 2010


Osteoporosis News powered by
MedPage Today
 
ACCME Disclaimer
 
Chapter 6 – Monitoring

Contributing Editor
E. Michael Lewiecki E. Michael Lewiecki, MD, FACP, FACE
Director
New Mexico Clinical Research & Osteoporosis Center
Albuquerque, New Mexico
top

Activity Goal
The goal of this CME activity is to address gaps in competence and practice performance by:
  • Stressing the importance of early screening and diagnosis of patients with or at risk for developing osteoporosis and fractures
  • Identifying the pathways involved in the pathophysiology of osteoporosis and fractures
  • Providing updates on current and emerging therapies with regard to mechanism of action, efficacy, safety, treatment regimen requirements for compliance, and their role in providing fracture prevention/reduction



Target Audience
This activity is designed for primary care physicians, including internists, family practitioners, gynecologists, and other clinicians involved in the care of patients with or at risk of developing osteoporosis and fractures.

Learning Objectives
•   Formulate a monitoring strategy for patients who are receiving pharmacologic therapy for osteoporosis to identify those who are suboptimal responders.
•   Evaluate the reasons for suboptimal response in patients receiving pharmacologic therapy for osteoporosis—including poor adherence and secondary risk factors—in order to optimize therapeutic benefit.

top

CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Projects In Knowledge designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CE Information: Nurses
Projects In Knowledge® (PIK) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Projects In Knowledge is also an approved provider by the California Board of Registered Nursing, Provider Number CEP-15227.

This activity is approved for 1.09 nursing contact hour(s).

DISCLAIMER: Accreditation refers to educational content only and does not imply ANCC, CBRN, or PIK endorsement of any commercial product or service.

CE Information: Pharmacists
Projects In Knowledge® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

This program has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. This chapter is worth up to 2.00 contact hours (0.2 CEUs). The ACPE Universal Program Number assigned to this knowledge activity is 0052-0000-10-397-H01-P.


top

Disclosure Information
The Disclosure Policy of Projects In Knowledge requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials. For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).

E. Michael Lewiecki, MD, FACP, FACE, has received grant/research support from Amgen Inc., Eli Lilly and Company, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc, Procter & Gamble, Hoffmann-La Roche Inc, sanofi-aventis, and Wyeth; is on the speakers bureau of Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, and Novartis Pharmaceuticals Corporation; and on the advisory board of Amgen Inc, Eli Lilly and Company, GlaxoSmithKline, Hoffmann-La Roche Inc, Novartis Pharmaceuticals Corporation, Upsher-Smith Laboratories Inc, and Wyeth; is a direct stock shareholder with General Electric, Proctor & Gamble, and Teva Pharmaceuticals; and is on the board of directors of International Society for Clinical Densitometry.

Nancy J. Nordenson, MT (ASCP), MFA has no significant relationships to disclose.

Peer Reviewer has disclosed no significant relationships.

Projects In Knowledge’s staff members have no significant relationships to disclose.

top

Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.

The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.

This CME/CE activity is provided by Projects In Knowledge solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.

Contract for Mutual Responsibility in CME/CE
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.

For more information on the contract, click here

Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.

top 1892.06


Launch Activity
 
Sponsor
Projects In Knowledge®


Peer Reviewed
This activity is supported by an educational donation provided by Amgen.


Release Date: February 24, 2010.

Termination Date: February 24, 2011.

Estimated time for completion of this activity:
CME: 2.0 hours
CE: 1.09 hours
CPE: 2.0 hours

CME/CE Instructions
To obtain CME/CE credit for this activity:
  1. Read the chapter carefully.
  2. Achieve a passing score on the posttest.
  3. Complete/submit the posttest and evaluation.
  4. Instantly access and print out your certificate.

There is no fee for this activity.
































 
 




ABOUT US  |  CONTACT US  |  CONTRACT  |  DIRECTIONS  |  PRIVACY POLICY  |  RESOURCES
Copyright © 1997-2010, Projects In Knowledge, Inc. All rights reserved.
PROJECTS IN KNOWLEDGE • Overlook at Great Notch • 150 Clove Road, 10th Floor • Little Falls, New Jersey 07424 (973) 890-8988